肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場予測（～2021年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 14
1.3.1 MARKETS COVERED 14
1.3.2 YEARS CONSIDERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 MARKET STAKEHOLDERS 15

2 RESEARCH METHODOLOGY 16
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.3 KEY DATA FROM SECONDARY SOURCES 21
2.4 KEY DATA FROM PRIMARY SOURCES 21
2.5 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 PULMONARY DRUG DELIVERY: MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: PULMONARY DRUG DELIVERY MARKET,
BY APPLICATION (2016) 28
4.3 PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE (2016 VS. 2021) 29
4.4 PULMONARY NEBULIZERS MARKET, BY TYPE (2016–2021) 29
4.5 GEOGRAPHIC SNAPSHOT: PULMONARY DRUG DELIVERY MARKET 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 MARKET DRIVERS 33
5.2.1.1 Increasing preference for pulmonary drug delivery as an alternate route of drug delivery 33
5.2.1.2 Increasing focus on the development of smart/digital inhalers 33
5.2.1.3 Increasing incidence of respiratory diseases 34
5.2.2 MARKET RESTRAINTS 35
5.2.2.1 Regulatory issues 35
5.2.2.2 Pricing pressure 35
 
5.2.3 MARKET OPPORTUNITIES 35
5.2.3.1 Emerging markets 35
5.2.3.2 Growth in online marketing channels 36
5.2.4 MARKET CHALLENGES 36
5.2.4.1 Issues with the stability of drugs 36
5.2.4.2 Deposition of aerosolized particles 36

6 PULMONARY DRUG DELIVERY MARKET, BY FORMULATION 37
6.1 INTRODUCTION 38
6.2 TYPE 38
6.2.1 SUSPENSION AEROSOLS 39
6.2.2 SOLUTION AEROSOLS 40
6.2.3 DRY POWDER FORMULATIONS 41
6.3 DEVICE TYPE 42
6.3.1 METERED DOSE INHALERS (MDIS) 43
6.3.2 DRY POWDER INHALERS (DPIS) 44
6.3.3 NEBULIZERS 45
6.3.3.1 Jet Nebulizers 46
6.3.3.2 Ultrasonic Nebulizers 47
6.3.3.3 Soft mist nebulizers 48

7 PULMONARY DRUG DELIVERY MARKET, BY CANISTER TYPE 49
7.1 INTRODUCTION 50
7.2 PLAIN CANISTERS 50
7.3 COATED CANISTER 51

8 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION 52
8.1 INTRODUCTION 53
8.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 54
8.3 ASTHMA 55
8.4 CYSTIC FIBROSIS 56
8.5 OTHER APPLICATIONS 57

9 PULMONARY DRUG DELIVERY MARKET, BY END USER 58
9.1 INTRODUCTION 59
9.2 HOSPITALS & CLINICS 60
9.3 HOME CARE SETTINGS 61
 

10 PULMONARY DRUG DELIVERY MARKET, BY REGION 62
10.1 INTRODUCTION 63
10.2 NORTH AMERICA 64
10.2.1 U.S. 69
10.2.2 CANADA 72
10.3 EUROPE 75
10.3.1 GERMANY 80
10.3.2 U.K. 83
10.3.3 FRANCE 86
10.3.4 REST OF EUROPE 89
10.4 ASIA 92
10.4.1 CHINA 97
10.4.2 INDIA 100
10.4.3 JAPAN 103
10.4.4 REST OF ASIA 106
10.5 REST OF THE WORLD 109

11 COMPETITIVE LANDSCAPE 112
11.1 OVERVIEW 112
11.2 MARKET RANK ANALYSIS 113
11.3 COMPETITIVE SITUATIONS AND TRENDS 114
11.3.1 COLLABORATIONS 115
11.3.2 PRODUCT LAUNCHES AND REGULATORY APPROVALS 116
11.3.3 ACQUISITIONS 117
11.3.4 EXPANSIONS 117

12 COMPANY PROFILES 118
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 118
12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 119
12.3 3M 121
12.4 GLAXOSMITHKLINE PLC 123
12.5 ASTRAZENECA PLC 125
12.6 BOEHRINGER INGELHEIM 128
12.7 MERCK & CO., INC. 130
12.8 NOVARTIS AG 132
12.9 OMRON CORPORATION 134
 
12.10 SUNOVION PHARMACEUTICALS INC. (A PART OF SUMITOMO DAINIPPON PHARMA CO., LTD.) 136
12.11 CIPLA INC. 138
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX 140
13.1 INSIGHTS FROM INDUSTRY EXPERTS 140
13.2 DISCUSSION GUIDE 141
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 145
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 147
13.5 AVAILABLE CUSTOMIZATIONS 148
13.6 RELATED REPORTS 149
13.7 AUTHOR DETAILS 150